Stoke Therapeutics, Inc.
Company Stats
- Market Cap
- $1.7B
- as of Sep 30, 2026
- Shares Outstanding
- 64.5M
- Free Float
- 87.6%
Income Statement
- Revenue
- $184.4M
- Operating Income
- -$20.6M
- Net Income
- -$6.9M
- EBITDA
- -$18.8M
- Revenue Growth, 3Y
- 145.9%
- FCF Margin, 3Y Avg
- -385.2%
- FCF Margin, Worst Year
- -941.7%
Cash Flow
- Free Cash Flow
- $44.9M
- FCF Yield
- 2.7%
- Owner FCF Yield
- 0.8%
Balance Sheet
- Cash & Equivalents
- $84.2M
Returns & Capital
- SBC, 3Y Avg
- $28.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $184.4M | $44.9M | 24.4% |
| FY2024 | $36.6M | -$87.1M | -238.1% |
| FY2023 | $8.8M | -$82.7M | -941.7% |
| FY2022 | $12.4M | -$35.8M | -288.8% |
| FY2021 | — | -$68.1M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back